首页> Scientific reports> Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.

Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Gamal,Shiha

第一单位： Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.;Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.

作者： Gamal,Shiha ^[1] ; Reham,Soliman ^[2] ; Mohamed,Elbasiony ^[1] ; Noureldien H E,Darwish ^[3] ; Shaker A,Mousa ^[4]

作者单位： Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.;Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. ^[1] Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.;Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt. ^[2] Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.;The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA. ^[3] The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA. shaker.mousa@acphs.edu.;Virothera Pharmaceuticals, Rensselaer, NY, USA. shaker.mousa@acphs.edu. ^[4]